Efficacy and Safety of Gluten Peptide-based Antigen-specific Immunotherapy (Nexvax2) in Adults with Coeliac Disease After Bolus Exposure to Gluten (reset Ced): An Interim Analysis of a Terminated Randomised, Double-blind, Placebo-controlled Phase 2 Study

Tye-Din, Jason A, Daveson, A James M, Goel, Gautam, Goldstein, Kaela E, Hand, Holly L, Neff, Kristin M, Popp, Alina, Taavela, Juha, Maki, Markku, Isola, Jorma, Williams, Leslie J, Truitt, Kenneth E, Anderson, Robert P, Adams, Atoya, Andrews, Jane M, Behrend, Clint E, Brown, Gregor J E, Chen Yi Mei, Swee Lin, Coates, Allan G, DiMarino, Anthony J, Ee, Hooi, Elliott, David E, Epstein, Roger M, Feyen, Bryan John, Fogel, Ronald P, Friedenberg, Keith Alan, Gearry, Richard B, Gerdis, Michael S, Michael J, Gupta, Vipin K, Holmes, Robert John, Holtmann, Gerald J, Idarraga, Samuel H, James, George W, King, Tim, Klein, Terry D, Kupfer, Sonia S, Lebwohl, Benjamin, Lowe, Matthew John, Murray, Joseph A, Newton, Eric B, Quinn, Dean, Radin, David M, Ritter, Timothy E, Stacey, Helen Lee, Strout, Cynthia B, Stubbs, Richard S, Thackwray, Susan Lynn, Trivedi, Vivek M, Weber, John R, Wilson, Scott A